drugset
Drugs / CM4620-IE
last change Mar 2023 re-read 3 minutes ago

CM4620-IE

Developed for
acute pancreatitis
Investigated by
CalciMedica, Inc.

Trials 1

today NCT03709342 · Ph 2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03709342 Jan → Mar 2019 acute pancreatitis CalciMedica, Inc. Completed No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2023-03-15 CalciMedica, Inc. FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND calcimedica.com ↗
2023-03-15 CalciMedica, Inc. CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy calcimedica.com ↗
2023-03-15 CalciMedica, Inc. CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy calcimedica.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CM4620-IE ClinicalTrials.gov intervention name — accepted as the source's own label NCT03709342 ↗
Route Intravenous “single IV infusion on Day 1 over 4 hours” NCT03709342 ↗